Job description:
 

We use science to save lives, and so can you.

We are currently recruiting for a Scientist III to join the Analytical Development and Technologies Group (ADT) within Analytical Services and Quality control department (ADQC). This is an office-based role with a focus on controlling assay life cycle from development to QC in accordance with scientific and regulatory requirements.

The purpose of the role is to

Our ADQC team supports the development of products through analytical testing to facilitate manufacturing and process development, ensuring appropriate quality controls and use of analytics.

Your responsibilities in this role would be:

• Management and justification of assay acceptance criteria
• Management of in-house control materials, including qualification studies to ensure fit-for-use
• Assisting in the development and transfer of assays when required
• Assist with investigations in accordance with correct methodologies and procedures under the direction of Subject Matter Expert/QC Manager/Line Manager

• Ensuring a high standard of record keeping and documentation of assays and investigations.
• Presentation of scientific data at internal meetings.
• Involvement in Analytical method transfer.

• Responsible for the completion of tasks about their criticality.
• Work will be conducted in accordance with the OXB Quality Management system.
• Writing and reviewing of departmental documentation and SOPs.
• Completion of Quality records (Change control, Deviation, and CAPAs) to a high level in a timely manner

We are looking for:

• Educated to a minimum of BSc Degree with basic experience of working in a related environment.
• An understanding of Virology and gene therapy would be an advantage.
• Technical experience in cell culture, qPCR or molecular biology.
• Proven abilities in critical thinking and trouble-shooting.
• Experience of working under regulatory requirements, e.g. GMP, GLP, GCP and/or Validation and Quality Management systems.
• Good working knowledge of Excel
• Working knowledge of JMP and/or Minitab an advantage

About Us:

Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

What’s in it for you:

• Highly competitive total reward packages
• Wellbeing programmes
• Development opportunities
• Welcoming, friendly, supportive colleagues
• A diverse and inclusive working environment
• Our values are: Deliver Innovation, Be Inspiring and Have Integrity
• State of the art laboratory and manufacturing facilities

We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment, and teamwork, and so can you.

Collaborate. Contribute. Change lives

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.  

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).  

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.